Glaukos Aktie

Glaukos für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A14VCK / ISIN: US3773221029

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
01.08.2025 07:54:17

Glaukos (GKOS) Q2 Revenue Jumps 30%

Glaukos (NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%. Non-GAAP earnings per share (EPS) came in at a loss of ($0.24), outperforming the anticipated ($0.26) non-GAAP loss. Both top-line and bottom-line results showed sharp improvements over the same period last year. The quarter was marked by ongoing strong adoption of its innovative glaucoma products in the U.S. and continued expansion in global markets. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Glaukos develops and commercializes innovative therapies for chronic eye diseases, including glaucoma, corneal disorders, and retinal diseases. Its leading treatments include micro-invasive glaucoma surgery (MIGS) devices, pharmaceutical implants, and therapies aimed at improving patient outcomes with less invasive approaches.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Glaukos Corpmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Glaukos Corp 70,00 2,94% Glaukos Corp
Q2 Holdings Inc 60,50 -2,42% Q2 Holdings Inc